Last reviewed · How we verify
NCT05463016
Impact of Color Correcting Lenses on Color Vision Deficiency
NA trial testing Experimental Group 1: Color Correcting Lenses in Color Blindness in 35 participants. Completed in 31 March 2024.
1 August 2023
Quick facts
| Lead sponsor | University of the Incarnate Word |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 35 |
| Start date | 28 July 2022 |
| Primary completion | 1 August 2023 |
| Estimated completion | 31 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Experimental Group 1: Color Correcting Lenses
- Placebo Group 1: Placebo Lenses
- Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses
- Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses
- Color Correcting Lenses in Subjects with Normal Color Vision
Conditions studied
- Color Blindness — all drugs for Color Blindness →
- Color Vision Defects — all drugs for Color Vision Defects →
- Color Blindness, Green — all drugs for Color Blindness, Green →
- Color Blindness, Red — all drugs for Color Blindness, Red →
Sponsor
University of the Incarnate Word
Who can join
18 and older, any sex, with Color Blindness or Color Vision Defects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To demonstrate improved color vision in subjects with color vision deficiencies while wearing color-correcting lenses and after color-correcting lense use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05463016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Color Blindness
Currently open trials in the same condition.
- NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
Other University of the Incarnate Word trials
Trials by the same sponsor.
- NCT05713981 — The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression · NA · completed
- NCT05482997 — Athlete Whey Protein Sensitivity: Prevalence and Performance · NA · completed
- NCT05990036 — The Outcome of Sports Vision Training on Collegiate Softball Players · NA · completed
- NCT04808869 — Effectiveness of Blood Flow Restriction During Aerobic Cycling · NA · completed
- NCT03968731 — Meibomian Gland Dysfunction Management With ZEST Protocol · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05463016 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of the Incarnate Word
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing